{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:07:28Z","timestamp":1780484848694,"version":"3.54.1"},"reference-count":25,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The optimal timing of surgery after preoperative fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy (ChT) in gastric cancer (GC) remains unclear. We aimed to evaluate the association between time to surgery (TTS) and pathological as well as survival outcomes in patients treated with perioperative FLOT. Materials and Methods: This retrospective cohort study included 76 patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who underwent curative-intent surgery after preoperative FLOT at a single tertiary center. TTS was defined as the interval between completion of preoperative FLOT and surgery. Patients were categorized into two groups according to TTS: \u22644 weeks and &gt;4 weeks. Pathological response (PR) was assessed using the Becker tumor regression grading system. The primary endpoint was PR, including tumor regression grade and pathological complete response (pCR). Secondary endpoint was overall survival (OS). Results: The median TTS was 31 days (IQR, 21\u201347). Forty-five (59.2%) patients underwent surgery within 4 weeks. Favorable PR was more frequently observed in the \u22644-week group. Becker TRG 0\u20131 was significantly more common among patients undergoing surgery within 4 weeks compared with those undergoing surgery after more than 4 weeks (26.2% vs. 6.5%, p = 0.03). Similarly, pCR was observed exclusively in the \u22644-week group (14.3% vs. 0%, p = 0.02). ypN0 status was numerically higher in the \u22644-week group (54.7% vs. 32.2%, p = 0.05). Postoperative complication rates did not differ significantly between groups (4.8% vs. 12.9%, p = 0.17). In multivariable Cox regression analysis, TTS was not independently associated with OS, whereas poor tumor differentiation remained an independent predictor of worse survival (HR 2.57, 95% CI 1.17\u20135.63, p = 0.01). Conclusions: Among patients treated with preoperative FLOT, surgery within 4 weeks was associated with improved PR without an apparent increase in postoperative morbidity. However, earlier surgery was not independently associated with improved OS. These findings suggest that prolonged delay after preoperative FLOT may not be necessary in clinically recovered patients and support the need for prospective multicenter studies to define the optimal surgical interval in FLOT-treated GC.<\/jats:p>","DOI":"10.3390\/medicina62061080","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:14:57Z","timestamp":1780395297000},"page":"1080","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does Timing Matter? Impact of Time to Surgery on Pathologic Response in Gastric Cancer Patients Treated with Perioperative FLOT"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-8446","authenticated-orcid":false,"given":"Beng\u00fc","family":"Dursun","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-507X","authenticated-orcid":false,"given":"Seher","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferit","family":"Ayd\u0131n","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ata T\u00fcrker","family":"Ar\u0131k\u00f6k","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ankara Etlik City Hospital, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial","volume":"393","author":"Homann","year":"2019","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"key":"ref_5","first-page":"1521","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","article-title":"Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial","volume":"17","author":"Hofheinz","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12957-023-03251-y","article-title":"Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: A systematic review and meta-analysis","volume":"21","author":"Ling","year":"2023","journal-title":"World J. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.21037\/tcr.2019.08.42","article-title":"Impact of the time from the completion of neoadjuvant chemotherapy to surgery on the outcomes of patients with gastric cancer","volume":"8","author":"Wu","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e162743","DOI":"10.1001\/jamasurg.2016.2743","article-title":"Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with esophageal cancer","volume":"151","author":"Haisley","year":"2016","journal-title":"JAMA Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3393\/ac.2018.01.01","article-title":"Optimal time interval for surgery after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: Analysis of health insurance review and assessment service data","volume":"34","author":"Kim","year":"2018","journal-title":"Ann. Coloproctol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.18632\/oncoscience.577","article-title":"Cancer cell repopulation after therapy: Which is the mechanism?","volume":"10","author":"Prakash","year":"2023","journal-title":"Oncoscience"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3748\/wjg.v24.i2.257","article-title":"Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes","volume":"24","author":"Liu","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, Y., Liu, Z., Shan, F., Ying, X., Zhang, Y., Li, S., Jia, Y., Li, Z., and Ji, J. (2020). Optimal timing to surgery after neoadjuvant chemotherapy for locally advanced gastric cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.613988"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1245\/s10434-020-09507-1","article-title":"Impact of the interval between neoadjuvant chemotherapy and gastrectomy on short-and long-term outcomes for patients with advanced gastric cancer","volume":"28","author":"Bausys","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.21037\/jgo.2017.08.13","article-title":"Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: A prospective, multi-center cohort study","volume":"8","author":"Achilli","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1245\/s10434-023-13151-w","article-title":"Tumor Regression Grade and Overall Survival following Gastrectomy with Preoperative Therapy for Gastric Cancer","volume":"30","author":"Sinnamon","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1245\/s10434-011-2165-6","article-title":"Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer","volume":"19","author":"Fujitani","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1007\/s11605-020-04688-2","article-title":"Tumor regression grade in gastric cancer after preoperative therapy","volume":"25","author":"Ikoma","year":"2021","journal-title":"J. Gastrointest. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.55730\/1300-0144.5404","article-title":"Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: Real-life data (Turkish Oncology Group)","volume":"52","author":"Erol","year":"2022","journal-title":"Turk. J. Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16241","DOI":"10.1038\/s41598-022-19883-1","article-title":"V-set and immunoglobulin domain containing 1 (VSIG1) as an emerging target for epithelial\u2013mesenchymal transition of gastric cancer","volume":"12","author":"Satala","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Satala, C.-B., Jung, I., and Gurzu, S. (2023). Mucin-phenotype and expression of the protein V-set and immunoglobulin domain containing 1 (Vsig1): New insights into gastric carcinogenesis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108697"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.suronc.2017.06.001","article-title":"The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma","volume":"33","author":"Sisic","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ero\u011flu, \u0130., M\u00f6hring, C., Sadeghlar, F., Ma\u0144czak, A., Yaz\u0131c\u0131, O., \u00d6zet, A., \u00d6zdemir, N., Gonzalez-Carmona, M.A., and G\u00fcrler, F. (2025). Efficacy and safety of neoadjuvant FLOT treatment for resectable gastric\/gastroesophageal junction adenocarcinoma in Turkish and German patients; a real-world data. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15043-6"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/10668969221105617","article-title":"Prognostic significance of tumour budding and desmoplastic reaction in intestinal-type gastric adenocarcinoma","volume":"31","author":"Pun","year":"2023","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41416-018-0202-y","article-title":"Tumour-stroma ratio and prognosis in gastric adenocarcinoma","volume":"119","author":"Kemi","year":"2018","journal-title":"Br. J. Cancer"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1080\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:25:04Z","timestamp":1780482304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061080"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061080","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}